Amisulpride in Schizophrenic Patients

Inclusion Criteria: Patients diagnosed as schizophrenia or schizophrenic disorder according to DSM-IV Patients who need new anti-psychotic drugs or need to change the medication due to aggravations of symptoms or recurrence Exclusion Criteria: Patients with positive symptoms in whom the disorder does not correspond to schizophrenic criteria. (e.g, schizoaffective disorder) Patients hypersensitive to the active ingredient or to other ingredients of the study drug Prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer Pheochromocytoma or Parkinson's disease Pregnancy or breast feeding Current or recently withdrawn from drug abuse or alcoholism Chronic renal failure and other internal or surgical disease which physician decides will be worsened by trial medication or that will affect the metabolism or effects of the trial medication Patients with previous histories and clinical improvement was not seen in spite of treatment with 2 anti-psychotics for over 8 weeks Slow heart rate of <55bpm, low blood potassium level, congenital prolongation of the QT interval Current treatment with a drug likely to cause markedly slow heart rate(<55bpm), low blood potassium level, slowing of intercardiac condition or prolongation of the QT interval The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.